Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 03, 2026 07:02 ET | Source: Medline Inc.

Medline Inc. announces launch of secondary offering of Class A common stock

NORTHFIELD, Ill., March 03, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (Nasdaq: MDLN) (“Medline”) announced today that certain selling stockholders affiliated with Blackstone Inc., The Carlyle Group...
February 23, 2026 21:42 ET | Source: Verisk Analytics, Inc.

Verisk Analytics, Inc. Prices Offering of Senior Notes

JERSEY CITY, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Verisk Analytics, Inc. (Nasdaq: VRSK) (“Verisk” or the “Company”), a leading strategic data analytics and technology partner to the global...
December 17, 2025 09:24 ET | Source: Kyverna Therapeutics, Inc.

Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock

EMERYVILLE, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX) (“Kyverna”), a clinical-stage biopharmaceutical company focused on developing cell therapies for...
December 11, 2025 16:01 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

WATERTOWN, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader...
December 10, 2025 00:14 ET | Source: Denali Therapeutics Inc.

Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

SOUTH SAN FRANCISCO, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced the pricing of its underwritten public offering of 9,142,857 shares of its...
December 09, 2025 23:30 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics Announces Pricing of Upsized $602 Million Public Offering

WATERTOWN, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader...
December 09, 2025 16:01 ET | Source: Denali Therapeutics Inc.

Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants

SOUTH SAN FRANCISCO, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced that it intends to offer and sell $200 million of shares of its common stock...
December 08, 2025 16:02 ET | Source: Dyne Therapeutics, Inc.

Dyne Therapeutics Announces Proposed Public Offering of Common Stock

WALTHAM, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically...
December 08, 2025 16:01 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics Announces Proposed Public Offering

WATERTOWN, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader...
December 01, 2025 22:37 ET | Source: Belite Bio, Inc

Belite Bio Announces Pricing of $350.0 Million Underwritten Public Offering of American Depositary Shares

SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics...